Loading...
Loading...
LABP| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 11.3M |
| Operating I/L | -11.3M |
| Other Income/Expense | -0.0M |
| Interest Income | 0.0M |
| Pretax | -11.3M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -11.3M |
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company specializing in the development of oral therapeutics for autoimmune diseases. The company's lead product candidates include omilancor and NX-13, targeting ulcerative colitis and Crohn's disease, and LABP-104 for systemic lupus erythematosus and rheumatoid arthritis. Additionally, the company has preclinical candidates such as LABP-66 for multiple sclerosis and Alzheimer's disease, LABP-69 for diabetic nephropathy and RA, LABP-73 for asthma and chronic obstructive pulmonary disease, and LABP-111 for nonalcoholic steatohepatitis and type 1 diabetes.
